KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Net Cash Flow (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Net Cash Flow for 16 consecutive years, with $171.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 247.29% year-over-year to $171.7 million, compared with a TTM value of $655.2 million through Dec 2025, up 287.69%, and an annual FY2025 reading of $655.2 million, up 287.69% over the prior year.
  • Net Cash Flow was $171.7 million for Q4 2025 at Alnylam Pharmaceuticals, down from $377.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $495.6 million in Q3 2022 and bottomed at -$283.7 million in Q1 2022.
  • Average Net Cash Flow over 5 years is $57.5 million, with a median of $44.9 million recorded in 2022.
  • The sharpest move saw Net Cash Flow crashed 8701.27% in 2021, then soared 2124.43% in 2024.
  • Year by year, Net Cash Flow stood at -$271.3 million in 2021, then increased by 23.15% to -$208.5 million in 2022, then dropped by 10.92% to -$231.2 million in 2023, then surged by 49.58% to -$116.6 million in 2024, then skyrocketed by 247.29% to $171.7 million in 2025.
  • Business Quant data shows Net Cash Flow for ALNY at $171.7 million in Q4 2025, $377.9 million in Q3 2025, and $66.1 million in Q2 2025.